Effects of antipsychotic drugs on cytokine networks

Journal of Psychiatric Research

Volumn 34, Issue 6, 2000, Pages 369-382

  Pollmächer, Thomas ^a   Haack, Monika ^a   Schuld, Andreas ^a   Kraus, Thomas ^a   Hinze Selch, Dunja ^a,b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Antipsychotic drugs; Cytokine networks

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; ENDOTOXIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HALOPERIDOL; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LEPTIN; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PHENOTHIAZINE DERIVATIVE; QUETIAPINE; RISPERIDONE; SERTINDOLE; STAPHYLOCOCCUS ENTEROTOXIN; THIOXANTHENE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; ZOTEPINE;

CYTOKINE PRODUCTION; FEVER; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0034495201     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(00)00032-7     Document Type: Article

References (137)

1. Bodyweight gain induced by psychotropic drugs - incidence, mechanisms and management
2. The influence of conditioning on immune responses
3. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States
4. Chlorpromazine-induced systemic lupus erythematosus
5. Journey from cachexia to obesity by TNF
6. Leptin
7. Medizinische Immunologie
8. Effect of psychotropic agents upon the blastogenic response of human T-lymphocytes
9. Induction of cytokine synthesis and fever suppresses REM sleep and improves mood in patients with major depression
10. Olanzapine versus placebo; results of a double-blind, fixed-dose olanzapine trial
11. Asymptomatic pancreatitis associated with clozapine
12. Protective effect of chlorpromazine against the lethality of interleukin 1 in adrenalectomized or actinomycin D-sensitized mice
13. Pharmacological activities of chlorpromazine involved in the inhibition of tumour necrosis factor production in vivo in mice
14. Chlorpromazine protection against interleukin- 1 and tumor necrosis factor-mediated activities in vivo
15. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients
16. A molecular basis for bidirectional communication between the immune and neuroendocrine systems
17. The effects of dexamethasone and chlorpromazine on tumour necrosis factor-alpha, interleukin-1 beta, interleukin-1 receptor antagonist and interteukin-10 in human volunteers
18. Temperaturanstiege und Bluteiweißveränderungen unter der Therapie mit Neuroleptika - unter besonderer Berücksichtigung des neuartigen Dibenzodiazepin-Derivates Clozapin
19. Serum leptin levels increase rapidly after initiation of clozapine therapy
20. Human responses to bacterial endotoxin
21. Differential effect of clozapine on weight; a controlled study
22. Body-mass index and mortality in a prospective cohort of U.S. adults
23. Clozapine-associated pancreatitis
24. Actions comparées de la prométhazine, de la chlorpromazine et de la cortisone chez la souris recevant des doses mortelles d'une endotoxine bacterienne
25. Regulation of autoimmunity by proinflanimatory cytokines
26. Tumour necrosis factor; strategies for improving the therapeutic index
27. The major histocompatibility complex region marked by HSP7O-1 and HSP7O-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups
28. Depressant effects of major tranquillizers on contact hypersensitivity to picryl chloride in the mouse
29. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist
30. Chlorpromazine-induced systemic lupus erythematosus; case report and review of the literature
31. Protective effect of chlorpromazine on TNF-mediated hapten-induced irritant reaction
32. Cytokines that regulate autoimmune responses
33. Clinical experience with ataractic therapy in tuberculous psychiatric patients
34. Cytokine blockade as a new strategy to treat rheumatoid arthritis; inhibition of tumor necrosis factor
35. Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoidsensitive and glucocorticoid-resistant models of endotoxic shock
36. Mitogenstimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms
37. Role of tumour necrosis factor and reactive oxygen intermediates in lipopolysaccharide-induced pulmonary oedema and lethality
38. Largactil in the treatment of tuberculosis
39. Mechanism of inhibition of tumor necrosis factor production by chlorpromazine and its derivatives in mice
40. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis
41. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
42. Hyperprolactinaemia in antipsychotic-treated patients - guidelines for avoidance and management
43. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities; a five-year naturalistic study
44. Clozapine-induced parotitis - an immunological cause?
45. Effects of clozapine on in vitro immune parameters - a longitudinal study in clozapine treated schizophrenic patients
46. Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight
47. Effects of clozapine on sleep: a longitudinal study
48. Sleep during clozapine-induced fever in a schizophrenic patient
49. Effects of antidepressants on weight and on the plasma levels of leptin, TNF-α and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine
50. Cytokines and the nervous system I; expression and recognition
51. Studies on the mechanism of drug-induced lipidosis. Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C
52. Chlorpromazine inhibits concanavalin A-induced liver injury independently of cytokine modulation
53. Human T lymphocyte activation by tumor promoters; role of protein kinase C
54. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
55. Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1
56. MHC class Jb-restricted cell responses to Listeria monocytogenes infection
57. Myocarditis and cardiomyopathy associated with clozapine
58. Effects of antipsychotic drugs on cellular immunity in mice
59. Fever; role of pyrogens and cryogens
60. Body weight and leptin plasma levels during treatment with antipsychotic drugs
61. Cytokines in sleep regulation
62. Interleukins and tumor necrosis factor as inhibitors of food intake
63. Characteristics of calmodulin binding to purified human lymphocyte plasma membranes
64. Short and long-term immunosuppressive effects of clozapine and haloperidol
65. Elevated CSF levels of interteukin-2 in neuroleptic-free schizophrenic patients
66. An adipocyte-central nervous system regulatory loop in the control of adipose homeostasis
67. Pharmacotherapy in tubercular schizophrenics
68. Evidence for an immune response in major depression - a review and hypothesis
69. In vivo immunomodulatory effects of clozapine in schizophrenia
70. Lower plasma CC 16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia; effects of antipsychotic drugs
71. Immune-inflammatory markers in schizophrenia; comparison to normal controls and effects of clozapine
72. The effects of selected drugs, including chlorpromazine and nonsteroidal anti-inflammatory agents, on polyclonal IgG synthesis and interleukin 1 production by human peripheral blood mononuclear cells in vitro
73. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status
74. Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice
75. Nerve growth factor in the neuroendocrine system
76. Inhibition of biological effects of endotoxins by phenothiazines
77. Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia; effects of clozapine treatment
78. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
79. Dose-dependent effects of endotoxin on human sleep
80. Psychoneuroimmunology and the cytokine action in the CNS - implications for psychiatric disorders
81. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia
82. Prolactin in autoimmune diseases
83. Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice
84. Inhibitory effect on LPS-induced tumor necrosis factor in calves treated with chlorpromazine or pentoxifylline
85. At issue; schizophrenia and rheumatoid arthritis: the negative association revisited
86. Agranulocytosis induced by certain phenothiazine derivatives
87. 51Cr release assay of clozapine-induced cytotoxicity; evidence for immunogenic mechanism
88. Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis
89. The influence of clozapine treatment on plasma granulocyte colony-stimulating (G-CSF) levels
90. Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol
91. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels
92. Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors
93. Influence of host defense activation on sleep in humans
94. Schlaf und Schläfrigkeit im Rahmen von Infektionen und im Rahmen experimenteller Immunmodulation beim Menschen
95. Thalidomide - current uses
96. Haloperidol and soluble interleukin-2 receptors
97. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia
98. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli
99. Possible association of parotitis with clozapine
100. Immunological dysfunction in schizophrenia; a systematic approach
101. Cytokines and the nervous system II; actions and mechanisms of action
102. Dissociation of immunosuppression by chlorpromazine and trifluoperazine from pharmacologic activities as dopamine antagonists
103. Hepatitis B vaccination in psychiatric patients
104. Human leptin stimulates proliferation and activation of human circulating monocytes
105. Multiple cytokines and acute inflammation raise mouse leptin levels; potential role in inflammatory anorexia
106. Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives
107. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine
108. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia
109. Cytokines in hematopoiesis; specificity and redundancy in receptor function
110. Inhibition of human natural killer (NK) activity by calcium channel modulators and a calmodulin antagonist
111. Report of a rare medical complication on clozapine
112. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men
113. Effects of clozapine on hematopoiesis and the cytokine system
114. Psychopharmacology of olanzapine - a review
115. Granulocyte and granulocyte-macrophage colony-stimulating factors
116. Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo
117. Tumor necrosis factor constellation polymorphism and clozapine-induced agranutocytosis in two different ethnic groups
118. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines; actions and mechanisms of action
119. Cytokine-cytokine interactions and the brain
120. Cytokines and anticytokines in the pathogenesis of sepsis
121. Effects on leukocytes after injection of tumor necrosis factor into healthy humans
122. Aberrant T cell-mediated immunity in untreated schizophrenic patients; deficient interleukin-2 production
123. 'Inflammatory' cytokines: neuromodulators in normal brain?
124. Ueber die Einwirkung fieberhafter Erkrankungen auf Psychosen
125. The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs
126. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients
127. Novel antipsychotics and new onset diabetes
128. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
129. Suppression of natural killer cell activity in mouse spleen lymphocytes by several dopamine receptor antagonists
130. Viruses, schizophrenia, and bipolar disorder
131. Chlorpromazine inhibits tumour necrosis factor synthesis and cytotoxicity in vitro
132. Chlorpromazine-induced immunopathy: progressive increase in serum IgM
133. Immunomodulation by thalidomide; systematic review of the literature and of unpublished observations